Melvin Churchill

Medicine · Health Sciences

15h-index3.7kcitations28works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Rheumatoid Arthritis Research and Therapies(17), Chronic Lymphocytic Leukemia Research(10), Autoimmune and Inflammatory Disorders Research(10), Spondyloarthritis Studies and Treatments(7), Psoriasis: Treatment and Pathogenesis(6)

Publications28 total

Model‐Informed Drug Development‐Based Bridging from Subcutaneous to Intravenous Secukinumab Dosing: Approval in Psoriatic Arthritis and Axial Spondyloarthritis
Clinical Pharmacology & Therapeutics·2025Open Access
Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase 3 Study
Arthritis & Rheumatology·2024· 3 citedOpen Access
Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study
The Journal of Rheumatology·2022· 15 citedOpen Access
Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study
Arthritis Research & Therapy·2022· 24 citedOpen Access
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial
The Lancet·2019· 208 cited
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
The Lancet·2018· 349 citedOpen Access
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
The Lancet·2017· 390 citedOpen Access
Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial
Arthritis Care & Research·2015· 41 citedOpen Access
A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol
Arthritis & Rheumatology·2015· 24 citedOpen Access
THU0433 Secukinumab Improves Physical Function, Quality of Life, Fatigue and Work Productivity in Patients with Active Psoriatic Arthritis in Future 2, A Phase 3 Trial
Annals of the Rheumatic Diseases·2015· 4 cited
FRI0004 Randomization to Patient-Reported RAPID3 versus Physician-Based CDAI Tools for Prediction of Treatment Response and Assessment of Patient-Reported Outcomes in Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Results from the PREDICT Study
Annals of the Rheumatic Diseases·2014· 2 cited
97. Final 5-Year Safety and Efficacy Results of a Phase 3, Randomized, Placebo-Controlled Trial of Golimumab in Methotrexate-NaïVe Patients with Rheumatoid Arthritis
Lara D. Veeken·2014· 3 cited
A Randomized Clinical Trial to Evaluate Two Doses of an Intra-Articular Injection of LMWF-5A in Adults with Pain Due to Osteoarthritis of the Knee
PLoS ONE·2014· 48 citedOpen Access
A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis
Arthritis Research & Therapy·2013· 105 citedOpen Access
Golimumab, a Human Anti–Tumor Necrosis Factor Monoclonal Antibody, Injected Subcutaneously Every 4 Weeks in Patients With Active Rheumatoid Arthritis Who Had Never Taken Methotrexate: 1‐Year and 2‐Year Clinical, Radiologic, and Physical Function Findings of a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study
Arthritis Care & Research·2013· 39 cited
FRI0178 Five-year safety and efficacy of golimumab in methotrexate-naïve patients with rheumatoid arthritis: final study results of the phase 3, randomized, placebo-controlled go-before trial
Annals of the Rheumatic Diseases·2013· 3 cited
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Methotrexate-naive Patients With Rheumatoid Arthritis
Queensland's institutional digital repository (The University of Queensland)·2013
Erratum: Golimumab, a human anti‐tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four‐week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis
Arthritis & Rheumatism·2010
Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis
Arthritis & Rheumatism·2009· 393 citedOpen Access
Golimumab, a new human Anti-TNF-alpha monoclonal antibody, administered subcutaneously everv 4 weeks in methotrexate-naive patients with active rheumatoid arthritis: A randomized, double-blind, placebo-controlled, GO-BEFORE study
DIAL (Catholic University of Leuven)·2008· 5 cited
page 1 of 2Next →

Frequent Co-authors

Peter Nash(9), Ingrid Strusberg(8), Patrick Durez(8), Eric Amante(8), Bernardo A. Pons‐Estel(8), Roy Fleischmann(6), Elizabeth C. Hsia(6), Alan Kivitz(6), Won Park(5), Stephen Xu(5), Paul Emery(4), Proton Rahman(4), Chenglong Han(4), Yiying Zhou(4), Larry W. Moreland(3), Mittie K. Doyle(3), Weichun Xu(3), Mahboob U. Rahman(3), Eva Dokoupilová(3), Mary P. Howell(3)